Gabapentin is one of the more commonly prescribed medications for stroke survivors, used primarily to treat central post-stroke pain and post-stroke seizures. About five percent of Medicare beneficiaries who survive a stroke now receive a new gabapentin prescription within six months of hospital discharge, and that number has been climbing over the past decade. Beyond pain and seizures, animal research has raised intriguing questions about whether gabapentin could help the brain rewire itself after a stroke, though that work remains far from clinical application. The drug’s role in stroke recovery is broader and more nuanced than most patients realize.
Why Pain After Stroke Is So Common
Pain is one of the most underappreciated complications of stroke. A large multicenter study found that roughly 30% of stroke survivors experience some form of pain, with rates climbing above 40% in the weeks and months following the event and settling around 32% in the chronic stage. Pain types shift over time: headache tends to appear in the first days after stroke, while musculoskeletal and shoulder pain peak in the subacute weeks, and spasticity-related pain builds later still.1Pain Medicine. Prevalence and Time Course of Post-Stroke Pain: A Multicenter Prospective Hospital-Based Study
Central post-stroke pain, often called CPSP, is a specific type of neuropathic pain caused by the stroke itself damaging brain areas that process sensation. A systematic review and meta-analysis estimated its overall prevalence at about 11% of all stroke survivors, but that figure masks wide variation: in people whose stroke hit the thalamus or brainstem, the rate can exceed 50%.2PubMed Central. Prevalence and Management Challenges in Central Post-Stroke Neuropathic Pain: A Systematic Review and Meta-analysis CPSP usually develops within the first six months after a stroke, though roughly a quarter of cases appear right at stroke onset and a small percentage emerge more than a year later. Symptoms include burning, freezing, or squeezing sensations on the affected side of the body, along with abnormal sensitivity to touch or temperature. The pain can last for years, and it takes a serious toll on quality of life.3BMJ. Central post-stroke pain: advances in clinical and preclinical research – Section: Clinical features and lesion site
Despite being this common, CPSP is frequently overlooked. One study found that fewer than a quarter of patients with central post-stroke pain were receiving any drug treatment for it.1Pain Medicine. Prevalence and Time Course of Post-Stroke Pain: A Multicenter Prospective Hospital-Based Study This treatment gap is one reason gabapentin has drawn attention: it addresses a real and underserved clinical problem.
How Gabapentin Performs Against Post-Stroke Pain
The evidence for gabapentin in CPSP, while not enormous, is encouraging. In one clinical study of 84 stroke survivors with central post-stroke pain, patients received 300 mg of gabapentin twice daily. After one month, about 60% of those patients showed a clinically meaningful reduction in pain scores.4PubMed Central. The Efficacy of Gabapentin in Patients with Central Post-stroke Pain That is a substantial response rate, especially in a condition where many patients fail to respond to standard pain relievers. Case reports have described patients who tried multiple oral analgesics without relief and then experienced significant improvement within two weeks of starting gabapentin.5PubMed. Central post-stroke pain syndrome: yet another use for gabapentin?
A network meta-analysis that compared several drugs used for CPSP ranked gabapentin at or near the top for pain relief on standard pain scales, outperforming medications like lamotrigine, duloxetine, amitriptyline, and carbamazepine on one measure, and falling just behind pregabalin on another.6PLOS ONE. Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review These rankings come with caveats: the individual trials feeding the meta-analysis were mostly small, and head-to-head comparisons between gabapentin and pregabalin in stroke patients are limited. Still, the overall picture is that gabapentin belongs in the first tier of pharmacological options for central post-stroke pain.
One thing worth noting: gabapentin does not work overnight for this kind of pain. Studies typically measure outcomes at four weeks or later. Patients starting gabapentin for CPSP should expect a gradual reduction in symptoms rather than immediate relief, and not everyone responds. The roughly 40% of patients who did not meet the threshold for meaningful improvement in the study above is a reminder that CPSP remains difficult to treat, and gabapentin is not a universal solution.
Post-Stroke Seizures and Epilepsy
Stroke is one of the leading causes of new-onset seizures in older adults. These seizures can occur within the first week after a stroke (early seizures) or emerge weeks to months later as post-stroke epilepsy. The choice of anti-seizure medication for stroke patients is tricky because many survivors are also taking blood thinners, antiplatelet drugs, and other medications that interact badly with older-generation seizure drugs like carbamazepine and phenytoin.
Gabapentin sidesteps most of those problems. It does not interact with anticoagulants or antiplatelet agents, and it does not harm bone density the way some older anti-seizure medications do. A review of the evidence found that gabapentin and lamotrigine are the only newer anti-seizure drugs with high-level evidence of being more effective than immediate-release carbamazepine in elderly patients. Gabapentin also remains the only anti-seizure drug specifically evaluated in stroke patients for long-term seizure freedom, showing strong results in that setting.7PubMed. Optimizing therapy of seizures in stroke patients For these reasons, low-dose gabapentin or lamotrigine is often considered first-line therapy for post-stroke seizures, particularly in older patients or anyone on anticoagulants.
Animal studies have added another angle. In rodent models, gabapentin given around the time of an experimentally induced stroke reduced seizure activity and, in some cases, decreased the amount of brain tissue damaged. One study in young mice found that high-dose gabapentin cut acute seizures and reduced brain shrinkage measured four weeks later.8PubMed Central. Gabapentinoids for the treatment of stroke – Section: Seizures after stroke These animal findings are interesting but should not be overinterpreted: the doses and timing used in rodents do not translate directly to human stroke care. Still, they suggest that gabapentin’s benefits in stroke may extend beyond simply calming overexcitable neurons.
Animal Research on Brain Rewiring
Perhaps the most surprising line of gabapentin research in stroke has nothing to do with pain or seizures. A 2022 study published in the journal Brain found that daily gabapentin administration in mice after an experimentally induced stroke promoted structural rewiring of the motor pathways that control limb movement. Specifically, nerve fibers from the uninjured side of the brain sprouted new branches that crossed the midline and formed new connections in the spinal cord, essentially building a detour around the damaged area.9PubMed Central. Harnessing cortical plasticity via gabapentinoid administration promotes recovery after stroke
The researchers confirmed this was not just anatomical: the new connections were functional. When they stimulated the uninjured side of the brain, mice that had received gabapentin showed increased activation of spinal neurons that control movement, and the new nerve fibers formed proper excitatory synapses in the right spinal cord layers. These mice also recovered skilled forelimb function, whether gabapentin was started one hour or one day after the stroke. Importantly, gabapentin also appeared to dampen maladaptive plasticity by reducing excessive excitability in spinal motor circuits, which can otherwise interfere with recovery.9PubMed Central. Harnessing cortical plasticity via gabapentinoid administration promotes recovery after stroke
This is an exciting finding, but the gap between a mouse stroke model and a human stroke patient is vast. No clinical trial has yet tested whether gabapentin improves motor recovery in human stroke survivors. The study does raise the possibility that some stroke patients already receiving gabapentin for pain or seizures might be getting an unrecognized secondary benefit, but that is speculative. It also raises the question of whether gabapentin started early after stroke, even in patients without pain or seizures, could improve outcomes. That question will require human trials to answer.
Spasticity After Stroke
Gabapentin is also sometimes used off-label for post-stroke spasticity, the involuntary muscle tightness and stiffness that commonly develops in the weeks and months following a stroke. Spasticity-related pain tends to peak in the chronic stage of stroke recovery, making it a persistent problem. Gabapentin is listed among the anticonvulsant medications used to manage spasticity from various causes, alongside more common options like baclofen, tizanidine, and dantrolene.10PubMed Central. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches
The evidence base for gabapentin specifically in post-stroke spasticity is thinner than it is for pain or seizures. It tends to be tried when first-line spasticity drugs are not tolerated or are insufficient on their own. In practice, when a stroke patient has both neuropathic pain and spasticity, gabapentin becomes an appealing choice because it may address both problems with a single medication, reducing pill burden.
Typical Dosing in Stroke Survivors
Gabapentin dosing for post-stroke pain in the clinical research typically starts at 300 mg twice daily.4PubMed Central. The Efficacy of Gabapentin in Patients with Central Post-stroke Pain For post-stroke seizures, doses of 900 to 1,800 mg per day have been used and well tolerated.8PubMed Central. Gabapentinoids for the treatment of stroke – Section: Seizures after stroke In general clinical practice, doctors often begin with a low dose and gradually increase it, partly because stroke survivors tend to be older and more sensitive to side effects.
Gabapentin is eliminated by the kidneys, not metabolized by the liver, which is one of its advantages in stroke patients who may be on multiple liver-processed medications. However, this also means kidney function matters. Older adults with reduced kidney function may need lower doses or longer intervals between doses. Your doctor will typically check kidney function before starting the drug and adjust accordingly.
The drug is usually taken two or three times a day, and it is important to space doses relatively evenly because gabapentin’s absorption becomes less efficient at higher individual doses. Splitting a daily amount across three doses often works better than taking it all at once. Missing doses or stopping abruptly can cause rebound symptoms, including increased pain or, in the case of seizure patients, a risk of breakthrough seizures.
Side Effects and Safety Concerns
Gabapentin’s side-effect profile is generally considered mild compared to older anticonvulsants, which is part of why it has become popular in the stroke population. The most common complaints are drowsiness, dizziness, and fatigue. In some patients, particularly older adults, gabapentin can cause unsteadiness that raises the risk of falls. Since many stroke survivors already struggle with balance, this is not a trivial concern. Other possible side effects include swelling of the hands and feet, blurred vision, and weight gain.
A more serious safety issue is what happens when gabapentin is combined with other sedating drugs. A study of more than 153,000 Medicare stroke survivors found that among those who started gabapentin or pregabalin after discharge, about 21% were simultaneously taking opioids and nearly 9% were also on benzodiazepines.11Health Services Research. Gabapentinoid Polypharmacy Among Medicare Beneficiaries During the Poststroke Recovery Period The combination of gabapentin with opioids or benzodiazepines increases the risk of excessive sedation and respiratory depression. Stroke survivors, who may already have compromised respiratory drive or swallowing difficulties, are particularly vulnerable. If you are prescribed gabapentin after a stroke and are also taking opioids or sleep aids, it is worth having an explicit conversation with your prescriber about whether those combinations are necessary.
The same study showed that gabapentinoid prescribing after stroke increased from about 3.8% of survivors in 2009 to nearly 6% by 2022.11Health Services Research. Gabapentinoid Polypharmacy Among Medicare Beneficiaries During the Poststroke Recovery Period This upward trend is worth watching. While gabapentin fills a real clinical need, rising use also means more patients exposed to the risks of polypharmacy, especially in a population already taking multiple medications for blood pressure, cholesterol, and blood clot prevention.
How Long Stroke Survivors Stay on Gabapentin
One question that does not get enough attention is how long stroke patients actually remain on gabapentin once it is started. A study of older Medicare beneficiaries who began gabapentin within 30 days of hospital discharge after a stroke identified three distinct patterns of use. About half of patients maintained steady, consistent use for at least a year. On the other end, roughly 43% dropped off quickly, falling below adequate medication coverage within the first two months. A small group, about 6%, gradually tapered off over eight months.12PubMed Central. Gabapentin Treatment Patterns Among Older Patients After Hospital Discharge for Acute Ischemic Stroke
The high rate of early discontinuation is striking. Some of those patients may have stopped because their pain resolved or their seizures were controlled and their doctor tapered the medication. But side effects, confusion about the drug’s purpose, or simple forgetfulness could also be at play. Gabapentin requires multiple daily doses, and adherence to any multi-dose medication declines over time, especially in patients managing several drugs simultaneously.
If you or a family member has been prescribed gabapentin after a stroke, it helps to understand what the drug is targeting. A patient taking gabapentin for seizure prevention needs a different conversation about stopping it than a patient taking it for pain. In either case, do not stop abruptly without medical guidance. Tapering slowly reduces the chance of withdrawal symptoms or a return of the condition the drug was managing.
Where Gabapentin Sits Among Post-Stroke Medications
Gabapentin is not the only option for any of its post-stroke uses, and understanding where it fits helps set realistic expectations. For central post-stroke pain, pregabalin performs similarly and is sometimes preferred because it can be dosed twice daily with more predictable absorption. Antidepressants like duloxetine and amitriptyline also have evidence in neuropathic pain, though amitriptyline carries more side effects in older adults, including dry mouth, constipation, and cardiac rhythm changes. Lamotrigine is another alternative that has been studied in CPSP.6PLOS ONE. Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review
For post-stroke seizures, gabapentin’s main advantage is its clean drug-interaction profile. Levetiracetam is another newer anti-seizure drug commonly used after stroke that shares this benefit, though it was not the focus of the stroke-specific studies that gave gabapentin its evidence base in this area.7PubMed. Optimizing therapy of seizures in stroke patients The choice between these medications often comes down to individual tolerability and whether the patient has overlapping conditions that one drug might address better than another.
For spasticity, gabapentin is generally a second- or third-line option behind baclofen and tizanidine. Botulinum toxin injections are also widely used for focal spasticity and work through an entirely different mechanism. In practice, many stroke survivors end up on combinations of these treatments, which is another reason to keep an eye on total medication load and sedation risk.